BioNature

BioNature is a biotechnology company dedicated to the development of innovative peptide-based drugs for the treatment of neurodegenerative diseases. The company's core technology, the BNP (BioNature Peptides) platform, enables the creation of chimeric peptides designed to cross the blood-brain barrier and activate neuroprotective pathways. Their primary focus includes conditions such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's, and Parkinson's disease. By targeting receptors like IGF-1 and GLP-1, BioNature seeks to provide disease-modifying therapies that address the underlying mechanisms of neuronal loss. The company's lead candidate, BNP-1, has shown promise in preclinical models of ALS by promoting neuronal survival and reducing neuroinflammation. BioNature operates as a private entity, leveraging intellectual property developed at Tel Aviv University to advance its pipeline of neuroprotective agents.